Course Type: On-Demand Webcourse 
Number of Credits: 1
Credit Type: CME/MOC

Get Started

Pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau.  The diagnosis of pustular psoriasis relies mainly on clinical features and is challenging. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association.

Current systemic treatment has involved cyclosporine, methotrexate or acitretin. The Japanese Dermatological Association has also published guidelines that include a treatment algorithm. However, it has been recognized that IL-36 cytokines are likely the key driver of the autoimmune response in pustular psoriasis. There are two novel, investigational monoclonal antibodies that target the IL-36 receptor. In addition, agents that target other molecules have also been investigated.

Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease will review the most recent guidelines for diagnosing, classifying, and assessing the severity of pustular psoriasis and provide information on current treatment guidelines and agents in development to manage this rare group of disorders.

Get Started


FACULTY
Alice B. Gottlieb, MD, PhD
Clinical Professor of Dermatology,
Department of Dermatology
Division of Rheumatology
Icahn School of Medicine at Mount Sinai
Medical Director, Department of Dermatology
Mount Sinai at Union Square
New York, NY

Abby S. Van Voorhees, MD
Professor and Chair,
Department of Dermatology 
Eastern Virginia Medical School
Norfolk, VA

 

 

 


PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

In collaboration with the National Psoriasis Foundation


SUPPORTER

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.